This study will be conducted as a randomized, double blind, double-dummy, placebo-controlled, parallel-group trial in patients diagnosed with narcolepsy. Volunteers for this trial will be required to make 5 visits over up to 14 weeks to a participating expert physician practitioner for various sleep and narcolepsy evaluations and diaries will also be collected. Participants will take assigned medications during the course of the trial. Subjects will have a 25% probability of receiving placebo for both drugs (modafinil and Xyrem). All subject volunteers must meet criteria for narcolepsy and have evidence of daytime sleepiness. Patients will not incur any personal medical expenses due to participation in this trial. The sponsor is covering all visit costs not covered by insurance and there are some funds for patient expenses such as travel.

Condition	Treatment or Intervention	Phase
Narcolepsy	Drug: sodium oxybate	Phase III

Further Study Details: 

Expected Total Enrollment:  200

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA

Patients will be included in the trial if they:

• Have signed and dated an informed consent prior to beginning protocol required procedures.
• Are willing and able to complete the entire trial as described in the protocol.
• Are 18 years of age or older.
• Fulfill the International Classification of Sleep Disorders criteria for the diagnosis of narcolepsy.
• Are taking stable doses of modafinil (200 to 600 mg/day) for the treatment of daytime sleepiness for a period of three months or greater and the modafinil dose has been stable for at least 1 month prior to entering this trial
• Females may be included who are surgically sterile, two years post-menopausal, or if of child-bearing potential, using a medically accepted method of birth control (e.g., barrier method with spermicide, oral contraceptive, or abstinence) and agree to continue use of this method for the duration of the trial.
• In the opinion of the investigator have adequate support for the duration of the trial to include transportation to and from the trial site. In addition, if in the investigator’s assessment it is clinically indicated, the patient is willing to not operate a car or heavy machinery for the duration of the trial or for as long as the investigator deems clinically indicated.

EXCLUSION CRITERIA

Patients will be excluded from the trial if they:

• Have received gamma-hydroxybutyrate in the last 30 days.
• Have taken any investigational therapy within the 30-day period prior to the initial screening visit (Visit 1) for this trial.
• Have sleep apnea syndrome, defined as an Apnea Index > 10 per hour or an AHI (Apnea Hypopnea Index) greater than 15 per hour, or have any other cause of daytime sleepiness, and have any other disorder(s) that can be considered a primary cause of excessive daytime sleepiness (e.g., severe periodic leg movement syndrome as determined by the investigator, sleep apnea, sleep deprivation).
• Are taking hypnotics, tranquilizers, antihistamines (except for non-sedating antihistamines), benzodiazepines or clonidine at the start of the baseline period. Patients taking anticonvulsants are not eligible to participate event if they are willing to washout anticonvulsants for the trial.
• Are experiencing any major illness, including unstable cardiovascular, endocrine, neoplastic, gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurological (other than narcolepsy/cataplexy), pulmonary, and/or renal disease which would place the patient at risk during the trial or compromise the objectives outlined in the protocol.
• Have psychiatric disorders, major affective or psychotic disorders, or other problems that, in the investigator’s opinion, would preclude the patient's participation and completion of this trial or compromise reliable representation of subjective symptoms.
• Have a current or recent (within one year) history of a substance use disorder including alcohol abuse as defined by the DSM-IV.
• Have a serum creatinine greater than 2.0 mg/dL, abnormal liver function tests (SGOT [AST] or SGPT [ALT] more than twice the upper limit of normal), or elevated serum bilirubin (more than 1.5 times the upper limit of normal), or pre-trial ECG results demonstrating clinically significant arrhythmias, greater than a first degree AV block or a history of myocardial infarction within the last six months.
• Have an occupation that requires variable shift work or routine night shift.
• Have a clinically significant history of seizure disorder either past or present, a history of clinically significant head trauma (i.e., concussion resulting in clinically significant loss of consciousness) or past invasive intracranial surgery, and are taking anticonvulsant medications.

Arizona
      Pulmonary Associates, PA, Phoenix,  Arizona,  85006,  United States
California
      Pacific Sleep Medicine Services, Inc., San Diego,  California,  92121,  United States
      St. Jude Medical Center -- Sleep Disorders Institute, Fullerton,  California,  92835,  United States
      Pacific Sleep Medicine Services, Inc., Los Angeles,  California,  90048,  United States
      Neuro-Therapeutics, Inc., Pasadena,  California,  91105,  United States
      Stanford Sleep Disorders Clinic, Stanford,  California,  94305,  United States
Florida
      Clinical Research Group of St. Petersburg, Inc., St. Petersburg,  Florida,  33707,  United States
Illinois
      Peoria Pulmonary Associates, Ltd, Peoria,  Illinois,  61603,  United States
Indiana
      The Center for Sleep and Wake Disorders/Midwest Neurology, Danville,  Indiana,  46122,  United States
Kentucky
      Chest Medicine Associates DBA -- Sleep Medicine Specialists, Louisville,  Kentucky,  40217,  United States
      Community Research & Sleep Management Institute, Crestview Hills,  Kentucky,  41017,  United States
      Graves Gilbert Clinic, Bowling Green,  Kentucky,  42101,  United States
Maryland
      The Center for Sleep & Wake Disorders, Chevy Chase,  Maryland,  20815,  United States
      Sleep Medicine Associates of Maryland, Towson,  Maryland,  21204,  United States
      Sleep Disorders Center -- Union Hospital of Cecil County, Elkton,  Maryland,  21921,  United States
Michigan
      Henry Ford Hospital, Detroit,  Michigan,  48202,  United States
Missouri
      Washington University Sleep Center, St. Louis,  Missouri,  63108,  United States
New Jersey
      New Jersey Neuroscience Institute at JFK Medical Center, Edison,  New Jersey,  08818,  United States
New York
      Strong Sleep Disorders Center, Rochester,  New York,  14618,  United States
      Sleep Disorders Center of Rochester, Rochester,  New York,  14618,  United States
North Carolina
      Raleigh Neurology Associates, Raleigh,  North Carolina,  27607,  United States
      ALL-TRIALS Clinical Research, LLC -- Summit Sleep Disorder, Winston Salem,  North Carolina,  27103,  United States
Ohio
      Community Research Management Associates,Inc., Cincinnati,  Ohio,  45219,  United States
      Cincinnati Clinic & Sleep Management Institute, Cincinnati,  Ohio,  45219,  United States
      CSC Research -- Grove City Sleep Diagnostic Center, Grove City,  Ohio,  43123,  United States
Pennsylvania
      Center for Sleep Medicine, Lafayette Hill,  Pennsylvania,  19444,  United States
      Lehigh Valley Hospital Sleep Disorders Center, Allentown,  Pennsylvania,  18105,  United States
      Capital Region Sleep Disorder Center, Carlisle,  Pennsylvania,  17013,  United States
South Carolina
      SleepMed of South Carolina, Columbia,  South Carolina,  29220,  United States
      Lowcountry Lung and Critical Care, PA, Charleston,  South Carolina,  29406-7108,  United States
South Dakota
      SDHRF Clinical Research Center, Sioux Falls,  South Dakota,  57104,  United States
      Sioux Valley Clinic -- Pulmonary, Sioux Falls,  South Dakota,  57105,  United States
      Sleep Disorders Center, Sioux Falls,  South Dakota,  57105,  United States
Texas
      SLEEP WALKER -- Sleep Disorders Center & Neurodiagnostics--Lung Diagnostics, Ltd., San Antonio,  Texas,  78229,  United States
      Bhupesh Dihenia, MD, Lubbock,  Texas,  79410,  United States
Vermont
      Vermont Medical Sleep Disorders Center, Inc., Essex Junction,  Vermont,  05452,  United States
France, Cedex 13
      Hopital Pitie Salpetriere -- Federation des Pathologies du sommeil, Paris,  Cedex 13,  75651,  France
France, Cedex 5
      Centre du sommeil -- Hopital Gui de Chauliac, Montpellier,  Cedex 5,  34295,  France
Germany
      Psychiatrische Universitatsklinik, Regensburg,  93042,  Germany
Switzerland
      Neurologische Poliklinik -- Universitats Spital Zurich, Zurich,  CH-8091,  Switzerland

Study chairs or principal investigators

William Houghton, MD,  Study Chair,  Orphan Medical   
Harry N Cook, MBA, RPh,  Study Director,  Orphan Medical   

Study ID Numbers:  OMC-SXB-22
Record last reviewed:  July 2004
Last Updated:  October 13, 2004
Record first received:  August 4, 2003
ClinicalTrials.gov Identifier:  NCT00066170
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08